Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Related news

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

ARGXArgenx2026-08-06 11:48 EST

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

CGEMCullinan Therapeutics, Inc.2026-09-24 11:00 EST

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

CGEMCullinan Therapeutics, Inc.2026-09-14 11:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

Lisata Therapeutics

Lisata Therapeutics is a precision oncology company focused on therapies designed to improve tumor penetration and enhance drug delivery into solid tumors. Its story is built around the idea that better access to tumors can improve the performance of other anti-cancer approaches.